{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T13:23:39Z","timestamp":1782566619871,"version":"3.54.5"},"reference-count":38,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Surg"],"published-print":{"date-parts":[[2023,11,1]]},"abstract":"Importance<\/jats:title>Hyperthermic intraperitoneal chemotherapy (HIPEC) followed by interval cytoreductive surgery (ICS) has shown survival benefits for patients with advanced-stage ovarian cancer. However, there is still a lack of consensus regarding the integration of HIPEC into clinical practice.<\/jats:p><\/jats:sec>Objective<\/jats:title>To evaluate the safety and effectiveness of ICS with HIPEC compared with ICS alone in clinical practice for patients with advanced-stage ovarian cancer.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This prospective, multicenter, comparative effectiveness cohort study enrolled 205 patients with stage III or IV ovarian cancer who had received at least 3 cycles of neoadjuvant chemotherapy followed by ICS with HIPEC or ICS without HIPEC at 7 Korean Gynecologic Oncology Group institutions between September 1, 2017, and April 22, 2022. Nine patients were excluded because they did not meet the inclusion criteria.<\/jats:p><\/jats:sec>Exposures<\/jats:title>Neoadjuvant chemotherapy followed by ICS with HIPEC or ICS without HIPEC.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was progression-free survival (PFS). Overall survival (OS) and the safety profile were the key secondary end points.<\/jats:p><\/jats:sec>Results<\/jats:title>This study included 196 patients (median age, 58.0 years [range, 38-82 years]), of whom 109 underwent ICS with HIPEC and 87 underwent ICS without HIPEC. The median duration of follow-up was 28.2 months (range, 3.5-58.6 months). Disease recurrence occurred in 128 patients (65.3%), and 30 patients (15.3%) died. Interval cytoreductive surgery with HIPEC was associated with a significant improvement in median PFS compared with ICS without HIPEC (22.9 months [95% CI, 3.5-58.6 months] vs 14.2 months [95% CI, 4.0-56.2 months]; P<\/jats:italic>\u2009=\u2009.005) and median OS (not reached [95% CI, 3.5 months to not reached] vs 53.0 [95% CI, 4.6-56.2 months]; P<\/jats:italic>\u2009=\u2009.002). The frequency of grade 3 or 4 postoperative complications was similar in both groups (ICS with HIPEC, 3 of 109 [2.8%] vs ICS without HIPEC, 3 of 87 [3.4%]; P<\/jats:italic>\u2009&amp;gt;\u2009.99). Among patients with recurrence, the frequency of peritoneal recurrence was lower in the ICS with HIPEC group than in the ICS without HIPEC group (21 of 64 [32.8%] vs 41 of 64 [64.1%]; P<\/jats:italic>\u2009=\u2009.001).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This study suggests that ICS in conjunction with HIPEC was associated with longer PFS and OS than ICS without HIPEC for patients with advanced-stage ovarian cancer and was not associated with higher rates of postoperative complications. The lower rate of peritoneal recurrence after HIPEC may be associated with improved OS.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamasurg.2023.3944","type":"journal-article","created":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T15:02:09Z","timestamp":1694012529000},"page":"1133","source":"Crossref","is-referenced-by-count":31,"title":["Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy"],"prefix":"10.1001","volume":"158","author":[{"given":"Jung-Yun","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong Jae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Hyuk","family":"Son","sequence":"additional","affiliation":[{"name":"Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunghoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Institute of Women\u2019s Life Medical Science, Yonsei University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Chul","family":"Choi","sequence":"additional","affiliation":[{"name":"Comprehensive Gynecologic Cancer Center, CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hoon","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Yun","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Korea University Medical Center, Korea University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Gy","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Kyung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ewha Womans University College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, South Korea; Korean Gynecologic Oncology Group, Seoul, South Korea"},{"name":"Korean Gynecologic Oncology Group, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk-Joon","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"15","key":"soi230059r1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.ejca.2015.07.022","article-title":"Survival of women with cancers of breast and genital organs in Europe 1999-2007: results of the EUROCARE-5 study.","volume":"51","author":"Sant","year":"2015","journal-title":"Eur J Cancer"},{"issue":"22","key":"soi230059r2","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/jnci\/djj443","article-title":"Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments.","volume":"98","author":"Kyrgiou","year":"2006","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"soi230059r3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3390\/jcm9041235","article-title":"Rethinking radical surgery in interval debulking surgery for advanced-stage ovarian cancer patients undergoing neoadjuvant chemotherapy.","volume":"9","author":"Lee","year":"2020","journal-title":"J Clin Med"},{"issue":"10","key":"soi230059r4","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.6004\/jnccn.2013.0142","article-title":"Ovarian cancer, version 2.2013.","volume":"11","author":"Morgan","year":"2013","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"soi230059r5","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/cancers14092308","article-title":"Dynamics of the tumor immune microenvironment during neoadjuvant chemotherapy of high-grade serous ovarian cancer.","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"soi230059r6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy.","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"soi230059r7","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1053\/ctrv.2001.0232","article-title":"Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy.","volume":"27","author":"Witkamp","year":"2001","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"soi230059r8","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer.","volume":"378","author":"van Driel","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"soi230059r9","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamasurg.2022.0143","article-title":"Survival after hyperthermic intraperitoneal chemotherapy and primary or interval cytoreductive surgery in ovarian cancer: a randomized clinical trial.","volume":"157","author":"Lim","year":"2022","journal-title":"JAMA Surg"},{"issue":"3","key":"soi230059r10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.ygyno.2020.09.022","article-title":"Current status of hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer in the United States.","volume":"159","author":"Charo","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"20","key":"soi230059r11","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"soi230059r12","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e3","article-title":"Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study.","volume":"30","author":"Lee","year":"2019","journal-title":"J Gynecol Oncol"},{"issue":"1","key":"soi230059r13","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2017.28.e6","article-title":"Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers.","volume":"28","author":"Jeon","year":"2017","journal-title":"J Gynecol Oncol"},{"key":"soi230059r14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.936099","article-title":"Interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in advanced-stage ovarian cancer: single-institution cohort study.","volume":"12","author":"Lee","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"soi230059r15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"20","key":"soi230059r16","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","article-title":"Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels.","volume":"19","author":"Rustin","year":"2001","journal-title":"J Clin Oncol"},{"issue":"3","key":"soi230059r17","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ygyno.2004.01.029","article-title":"Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.","volume":"94","author":"Chi","year":"2004","journal-title":"Gynecol Oncol"},{"issue":"1","key":"soi230059r19","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer.","volume":"354","author":"Armstrong","year":"2006","journal-title":"N Engl J Med"},{"issue":"16","key":"soi230059r20","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study.","volume":"37","author":"Walker","year":"2019","journal-title":"J Clin Oncol"},{"key":"soi230059r21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jconrel.2018.04.029","article-title":"Hyperthermia-mediated drug delivery induces biological effects at the tumor and molecular levels that improve cisplatin efficacy in triple negative breast cancer.","volume":"282","author":"Dunne","year":"2018","journal-title":"J Control Release"},{"issue":"10","key":"soi230059r22","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1038\/sj.bjc.6605066","article-title":"Targeting HSP90 for cancer therapy.","volume":"100","author":"Mahalingam","year":"2009","journal-title":"Br J Cancer"},{"issue":"24","key":"soi230059r23","doi-asserted-by":"publisher","first-page":"9851","DOI":"10.1073\/pnas.1101053108","article-title":"Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition.","volume":"108","author":"Krawczyk","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"soi230059r24","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/ijc.v151.8","article-title":"Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial.","volume":"151","author":"Koole","year":"2022","journal-title":"Int J Cancer"},{"issue":"6","key":"soi230059r25","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1136\/ijgc-2020-001231","article-title":"Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"soi230059r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100098","article-title":"Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery.","volume":"6","author":"El Hajj","year":"2021","journal-title":"ESMO Open"},{"issue":"10","key":"soi230059r27","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","article-title":"Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.","volume":"363","author":"Vergote","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"soi230059r28","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","article-title":"Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis.","volume":"20","author":"Bristow","year":"2002","journal-title":"J Clin Oncol"},{"issue":"1","key":"soi230059r29","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/JCO.2007.13.1953","article-title":"Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study.","volume":"26","author":"Winter","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"soi230059r30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ygyno.2006.06.028","article-title":"The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.","volume":"103","author":"Eisenhauer","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"1","key":"soi230059r31","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12885-020-6688-8","article-title":"Germline BRCA, chemotherapy response scores, and survival in the neoadjuvant treatment of ovarian cancer.","volume":"20","author":"Lee","year":"2020","journal-title":"BMC Cancer"},{"issue":"7","key":"soi230059r32","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/ijc.v146.7","article-title":"Genomic profiling of the residual disease of advanced high-grade serous ovarian cancer after neoadjuvant chemotherapy.","volume":"146","author":"Lee","year":"2020","journal-title":"Int J Cancer"},{"issue":"1","key":"soi230059r33","first-page":"45","article-title":"Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy.","volume":"7","author":"Goodman","year":"2016","journal-title":"J Gastrointest Oncol"},{"issue":"3","key":"soi230059r34","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e53","article-title":"Effect of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on relapse pattern in primary epithelial ovarian cancer: a propensity score based case-control study.","volume":"29","author":"Ceresoli","year":"2018","journal-title":"J Gynecol Oncol"},{"issue":"12","key":"soi230059r35","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1136\/ijgc-2020-001825","article-title":"Central radiology assessment of the randomized phase III open-label OVHIPEC-1 trial in ovarian cancer.","volume":"30","author":"Koole","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"13","key":"soi230059r36","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1245\/s10434-012-2496-y","article-title":"Perioperative management of patients undergoing cytoreductive surgery combined with heated intraperitoneal chemotherapy for peritoneal surface malignancy: a multi-institutional experience.","volume":"19","author":"Bell","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"soi230059r37","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/635314","article-title":"Pulmonary complications following cytoreductive surgery and perioperative chemotherapy in 147 consecutive patients.","volume":"2012","author":"Preti","year":"2012","journal-title":"Gastroenterol Res Pract"},{"issue":"2","key":"soi230059r38","doi-asserted-by":"publisher","first-page":"235","DOI":"10.21037\/jgo","article-title":"The effect of intraoperative fluid administration on outcomes of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy.","volume":"10","author":"Shamavonian","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"soi230059r18","unstructured":"National Cancer Institute, National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Published November 27, 2017. Accessed July 27, 2023. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"}],"container-title":["JAMA Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/articlepdf\/2809263\/jamasurgery_lee_2023_oi_230059_1699372325.88766.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:06:28Z","timestamp":1699459588000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamasurgery\/fullarticle\/2809263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamasurg.2023.3944","relation":{},"ISSN":["2168-6254"],"issn-type":[{"value":"2168-6254","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}